Artiva Biotherapeutics, Inc.
NASDAQ:ARTVBiotechnology
-$0.34 today
- Market cap
- $186.36M
- Beta
- 2.40
- P/E (TTM)
- -2.7
- EPS (TTM)
- -$3.53
Volume 0.97M
Average 0.48M
ARTV Total Liabilities
Everything the company owes to creditors and other parties.
Artiva Biotherapeutics, Inc.NASDAQ: ARTV
Total Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total liabilities falls 19.4% from a year ago
Total liabilities stood at $18.11M at the end of Q1 FY2026, down 19.4% from a year earlier and down 13.6% from the prior quarter. Over 3 fiscal years it compounded at -57.5% a year.
Context
- Total liabilities amounted to 17.1% of total assets at the end of Q1 FY2026, up 5.3 pp from a year earlier.
- Total liabilities increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total liabilities keeps falling in the next quarterly balance sheet after a -19.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 20.97M USD
- Year-over-year change
- -8.6%
- 4-year CAGR
- -46.6%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 20.97M | -8.6% |
| FY2024 | 2024-12-31 | 22.94M | -91.4% |
| FY2023 | 2023-12-31 | 267.13M | -2.4% |
| FY2022 | 2022-12-31 | 273.75M | +5.8% |
| FY2021 | 2021-12-31 | 258.78M | — |
Total Liabilities vs competitors
How ARTV compares with its peers on the latest reported figures
- Peers report in different currencies, so total liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -19.4% is the 6th highest of 9, against a peer median of -14.1%.
- Total liabilities amounts to 17.1% of total assets for ARTV, versus a peer median of 26.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $308.88M USD | -11.0% | +17.3% | 127.6% | |
| Mar 2026 | $78.01M USD | +1.8% | -29.0% | 78.5% | |
| Mar 2026 | $70.39M USD | -20.6% | -15.2% | 27.8% | |
| Mar 2026 | $67.79M USD | -9.7% | -29.5% | 47.1% | |
| Mar 2026 | $26.98M USD | -17.2% | -8.4% | 15.1% | |
ARTVArtiva Biotherapeutics, Inc. | Mar 2026 | $18.11M USD | -19.4% | -57.5% | 17.1% |
| Dec 2025 | $14.1M USD | +54.6% | -5.2% | 25.1% | |
| Mar 2026 | €12.01M EUR | -27.4% | -0.9% | 24.5% | |
| Mar 2026 | $6.29M USD | -34.4% | -33.3% | 6.2% | |
| Peer median (excluding ARTV) | — | -14.1% | -11.8% | 26.5% | |
Competitors are the stored peer set for ARTV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 160.92M | 102.53M | 53.5M | 40.24M | 26.7M |
| Short-term Investments | 0 | 0 | 23.47M | 145.19M | 81.31M |
| Net Receivables | 468K | 525K | 1.76M | 146K | 767K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 1.62M | 1.09M | 3.06M | 3.89M |
| Total Current Assets | 162.29M | 104.68M | 79.82M | 188.63M | 112.67M |
| Property, Plant & Equipment (Net) | 4.08M | 27.62M | 24.64M | 20.43M | 17.36M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 245K | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 3.56M | 517K | 650K | 525K | 919K |
| Total Non-current Assets | 7.64M | 28.38M | 25.29M | 20.95M | 18.27M |
| Total Assets | 169.93M | 133.05M | 105.11M | 209.58M | 130.94M |
| Account Payables | 1.44M | 1.1M | 614K | 1.12M | 355K |
| Short-term Debt | 0 | 0 | 0 | 0 | 3.06M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 7.3M | 10.89M | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 0 | 0 | 2.1M |
| Total Current Liabilities | 19.31M | 25.63M | 12.23M | 12.25M | 13.09M |
| Long-term Debt | 0 | 0 | 0 | 0 | 7.88M |
| Deferred Tax Liabilities | 216.41M | 216.41M | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 21.68M | 15.64M | 0 | 0 | 0 |
| Other Non-current Liabilities | 81K | 115K | 241.59M | 73K | 0 |
| Total Non-current Liabilities | 239.48M | 248.13M | 254.9M | 10.69M | 7.88M |
| Total Liabilities | 258.78M | 273.75M | 267.13M | 22.94M | 20.97M |
| Common Stock | 0 | 0 | 0 | 3K | 3K |
| Retained Earnings | (93.8M) | (152.59M) | (181.31M) | (246.68M) | (330.55M) |
| Accumulated OCI | 0 | 0 | 308K | (129K) | 103K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | (88.86M) | (140.7M) | (162.02M) | 186.64M | 109.97M |
| Total Debt | 1.74M | 19.45M | 16.91M | 14.35M | 10.94M |
| Net Debt | (159.18M) | (83.08M) | (36.59M) | (25.88M) | (15.76M) |
Artiva Biotherapeutics, Inc.
NASDAQ:ARTV
Intrinsic Alpha fair value
Locked
Current Price
$3.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.